Episode 1- It's Time To Understand CAR-T Therapy For B-Cell Lymphoma: Earlier Indications Coming To A Community Near You

Estimated Time
1.0 hour

Release Date
Feb 24, 2022

Expiration Date
Apr 08, 2023

It’s time to understand CAR-T therapy for B-cell lymphoma: Earlier indications coming to a community near you, episode 1 of the 4-part educational initiative, The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes, is designed for community-based oncology clinicians. This CE activity includes conversations among CAR-T experts and a community clinician; it includes animations, patient video clips, and numerous downloadable resources including a directory of CAR-T treatment centers organized by state.
This activity explains what CAR-T therapy is and how it works; a special guest highlights key data from completed and ongoing trials of CAR-T therapies that were presented during the recent hematology conference.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated.
For pharmacists, Medical Learning Institute, Inc. will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.


Accreditation and Disclosure Information

Target Audience
This CE activity is intended for hematologists-oncologists, fellows, NPs, PAs, nurses, pharmacists, navigators, social workers, case managers engaged in the care of patients with R/R B-cell lymphomas.
Educational Objectives
After completing this CE activity, the participant should be better able to:
  • Evaluate the benefits and risks of CAR T-cell therapy in relation to those of other treatments
  • Identify patients who are candidates for CAR T-cell therapy
  • Interpret the clinical significance of new and emerging data regarding CAR T-cell therapy

Accreditation, Support and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society.   Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Educational Partner Statement
This activity is developed with our educational partner, The Leukemia & Lymphoma Society.
Support Statement
This CE activity is supported through an educational grant from Bristol Myers Squibb.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-22-008-H01-P
Type of Activity: Application
AAPA Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 4/8/2023. PAs should only claim credit commensurate with the extent of their participation.
Social Worker Continuing Education
As a Jointly Accredited Organization, Medical Learning Institute, Inc. (MLI) is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. MLI maintains responsibility for the course.
Social workers completing this course receive 1.0 General Social Work continuing education credits.
CCMC Contact Hours
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board-certified case managers. This course is approved for 1.0 CE contact hour(s).
Activity code: I00049629. Approval Number: 220000473. To claim these CEs, log into your CCMC Dashboard at www.ccmcertification.org.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity. 
Faculty Disclosures
Sergio A. Giralt, MD, FACP
Melvin Berlin Family Chair in Myeloma Research
Professor of Medicine
Weill Cornell Medical College
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Memorial Sloan Kettering Cancer Center
New York, NY
Sergio A. Giralt, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Actinium Pharmaceuticals, Inc., Amgen, Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Jazz Pharmaceuticals, Janssen Pharmaceuticals, Omeros Corporation, Pfizer Inc., and Sanofi.
Research Grant from Actinium Pharmaceuticals, Inc, Amgen, Bristol Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, Omeros Corporation, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Company.
Sanjay K. Juneja, MD
Hematology, Medical Oncology
Chief of Oncology Line           
Baton Rouge General  Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Sanjay K. Juneja, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Gilead Sciences, Inc. and xCures.
Speakers’ Bureau with AstraZeneca Pharmaceuticals and Merck & Co., Inc.
Stock Ownership with Phenomune and xCures.
Independent Contractor for xCures.
Rayne H. Rouce, MD, BS
Associate Professor
Department of Pediatrics
Texas Children’s Cancer Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX
Rayne H. Rouce, MD, BS, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Novartis Pharmaceuticals Corporation and Pfizer Inc.
Research Grant from Tessa Therapeutics.
Stephen J. Schuster, MD
Professor of Medicine, University of Pennsylvania
Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma
Director, Lymphoma Program and Lymphoma Translational Research
Abramson Cancer Center, University of Pennsylvania
Philadelphia, PA
Stephen J. Schuster, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for AstraZeneca Pharmaceuticals, BeiGene, Celgene Corporation/Bristol Myers Squibb, Genentech, Inc./F. Hoffmann-La Roche, Incyte Corporation, Janssen Pharmaceuticals, Legend Biotech, MorphoSys AG, Mustang Bio, Inc., Nordic Nanovector, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals.
Research Grant from Celgene Corporation, Genentech, Inc./F. Hoffmann-La Roche, and Novartis Pharmaceuticals Corporation.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Laurie Adami
Laurie Adami has no relevant financial relationship with ineligible companies to disclose for this educational activity. 
Sonia Su
Sonia Su has no relevant financial relationship with ineligible companies to disclose for this educational activity. 
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider and The Leukemia & Lymphoma Society, the joint provider do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Lauren Berger, MPH
The Leukemia & Lymphoma Society
Lauren Berger, MPH, has a financial interest/relationship or affiliation in the form of:
Stock Ownership with Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Organon & Co., Pfizer Inc., and Viatris Inc.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
About This Activity
Medical Learning Institute, Inc. and The Leukemia and Lymphoma Society are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. and The Leukemia and Lymphoma Society.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

Copyright © 2022 Medical Learning Institute, Inc | All Rights Reserved


On June 24, 2022, the Food and Drug Administration approved lisocabtagene maraleucel (liso-cel) for adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after one prior therapy. In the pivotal Phase 3 TRANSFORM trial, a single infusion of liso-cel significantly outperformed the standard of care with median event-free survival of 10.1 months vs. 2.3 months and a well-established safety profile. Approval was also based on data from the Phase 2 PILOT study, a trial of a CAR T-cell therapy in patients with primary refractory or relapsed LBCL who are not considered candidates for transplant, in which liso-cel delivered deep and durable responses.
For additional information see:
On April 1, 2022, the Food and Drug Administration approved axicabtagene ciloleucel (axi-cel) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy (CIT) or relapses within 12 months of first-line CIT. The approval was based on ZUMA-7, a randomized, open-label, multicenter trial that demonstrated a statistically significant and clinically meaningful improvement in event-free survival and complete response rates. The safety of axi-cel was manageable and at least consistent with that of its use in third-line therapy.

For additional information see: